JP2022500448A5 - - Google Patents
Info
- Publication number
- JP2022500448A5 JP2022500448A5 JP2021514336A JP2021514336A JP2022500448A5 JP 2022500448 A5 JP2022500448 A5 JP 2022500448A5 JP 2021514336 A JP2021514336 A JP 2021514336A JP 2021514336 A JP2021514336 A JP 2021514336A JP 2022500448 A5 JP2022500448 A5 JP 2022500448A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- pharmaceutical composition
- composition according
- inhibitor
- antibody
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024124104A JP2024153816A (ja) | 2018-09-14 | 2024-07-31 | 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731351P | 2018-09-14 | 2018-09-14 | |
| US62/731,351 | 2018-09-14 | ||
| PCT/IB2019/057745 WO2020053833A1 (en) | 2018-09-14 | 2019-09-13 | Methods for modulating regulatory t cells and inhibiting tumor growth |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024124104A Division JP2024153816A (ja) | 2018-09-14 | 2024-07-31 | 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022500448A JP2022500448A (ja) | 2022-01-04 |
| JPWO2020053833A5 JPWO2020053833A5 (https=) | 2022-08-29 |
| JP2022500448A5 true JP2022500448A5 (https=) | 2022-08-29 |
Family
ID=68393033
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514336A Pending JP2022500448A (ja) | 2018-09-14 | 2019-09-13 | 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法 |
| JP2024124104A Pending JP2024153816A (ja) | 2018-09-14 | 2024-07-31 | 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024124104A Pending JP2024153816A (ja) | 2018-09-14 | 2024-07-31 | 制御性ｔ細胞を調節し腫瘍増殖を阻害する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220049010A1 (https=) |
| EP (1) | EP3849666B1 (https=) |
| JP (2) | JP2022500448A (https=) |
| CN (2) | CN121534175A (https=) |
| AU (2) | AU2019340475B2 (https=) |
| CA (1) | CA3109563A1 (https=) |
| WO (1) | WO2020053833A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2990885A1 (en) | 2015-06-30 | 2017-01-05 | Sanford-Burnham Medical Research Institute | Btla fusion protein agonists and uses thereof |
| CN112168820B (zh) * | 2019-07-05 | 2023-09-29 | 中国科学院生物物理研究所 | SRCAP ATPase抑制剂在结直肠癌治疗中的应用 |
| WO2021152548A1 (en) * | 2020-01-30 | 2021-08-05 | Benitah Salvador Aznar | Combination therapy for treatment of cancer and cancer metastasis |
| GB202007099D0 (en) | 2020-05-14 | 2020-07-01 | Kymab Ltd | Tumour biomarkers for immunotherapy |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO20004844L (no) * | 2000-09-27 | 2002-05-10 | Thia Medica As | Fettsyre analoger for behandling av proliferative hudsykdommer |
| KR20070022197A (ko) * | 2003-11-05 | 2007-02-26 | 팔링겐, 인코포레이티드 | Ｃｄｉｍ 결합 항체의 증강된 ｂ 세포 세포독성 |
| JP2008521814A (ja) * | 2004-11-24 | 2008-06-26 | シェーリング コーポレイション | Ｄａｐ−１０およびその使用 |
| JP2012149004A (ja) * | 2011-01-18 | 2012-08-09 | Theravalues Corp | 核内受容体の賦活剤 |
| CA2988119A1 (en) * | 2015-06-03 | 2016-12-08 | Dana-Farber Cancer Institute, Inc. | Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy |
| EP3650468A1 (en) * | 2015-09-29 | 2020-05-13 | Fundació Institut de Recerca Biomèdica (IRB Barcelona) | Targeting metastasis stem cells through a fatty acid receptor (cd36) |
| WO2018029336A1 (en) * | 2016-08-12 | 2018-02-15 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for determining whether a subject was administered with an activator of the ppar beta/delta pathway. |
| GB201802307D0 (en) * | 2018-02-13 | 2018-03-28 | Vib Vzw | CD36 antagonists for use in melanoma treatment |
-
2019
- 2019-09-13 CA CA3109563A patent/CA3109563A1/en active Pending
- 2019-09-13 CN CN202511335959.5A patent/CN121534175A/zh active Pending
- 2019-09-13 AU AU2019340475A patent/AU2019340475B2/en active Active
- 2019-09-13 JP JP2021514336A patent/JP2022500448A/ja active Pending
- 2019-09-13 CN CN201980060377.7A patent/CN112703039A/zh active Pending
- 2019-09-13 WO PCT/IB2019/057745 patent/WO2020053833A1/en not_active Ceased
- 2019-09-13 EP EP19795641.0A patent/EP3849666B1/en active Active
- 2019-09-13 US US17/274,498 patent/US20220049010A1/en not_active Abandoned
-
2024
- 2024-07-31 JP JP2024124104A patent/JP2024153816A/ja active Pending
-
2025
- 2025-07-17 AU AU2025205589A patent/AU2025205589A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022500448A5 (https=) | ||
| Zhang et al. | Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy | |
| Chang et al. | Combination therapy with bispecific antibodies and PD-1 blockade enhances the antitumor potency of T cells | |
| Yonezawa et al. | Boosting cancer immunotherapy with anti-CD137 antibody therapy | |
| TWI902089B (zh) | 引導及導航控制蛋白質以及彼之製造及使用方法 | |
| JP2019500891A5 (https=) | ||
| JP2025023921A (ja) | ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法 | |
| JP2019521645A5 (https=) | ||
| RU2018135247A (ru) | БИСПЕЦИФИЧЕСКИЕ АНТИТЕЛА К CD25 И Fc ГАММА-РЕЦЕПТОРУ ДЛЯ ЭЛИМИНАЦИИ ОПУХОЛЕСПЕЦИФИЧЕСКИХ КЛЕТОК | |
| JP2019513725A5 (https=) | ||
| RU2019115428A (ru) | Способы лечения рака, включающие связывающие tigit агенты | |
| JP2020522495A (ja) | 抗ｌａｇ−３抗体、ｐｄ−１経路阻害剤および免疫療法剤の組み合わせを含む組成物 | |
| JP2021531764A5 (https=) | ||
| JP2018503365A5 (https=) | ||
| JP2017516489A5 (https=) | ||
| JP2016525117A5 (https=) | ||
| JP2020503273A5 (https=) | ||
| JP2019500892A5 (https=) | ||
| HRP20221226T1 (hr) | Protutijela protiv pd-1 i postupci njihove upotrebe | |
| JP2017506067A5 (https=) | ||
| JP2018520650A5 (https=) | ||
| TW201825511A (zh) | 表現免疫檢查點調節子的溶瘤病毒 | |
| JP2017511687A5 (https=) | ||
| RU2017115315A (ru) | Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения | |
| Urbanska et al. | Targeted cancer immunotherapy via combination of designer bispecific antibody and novel gene-engineered T cells |